Want to join the conversation?
$MYL, which competes with $PFE, $JNJ and $GSK, said it reaffirms its FY16 EPS of $2.38-2.43, the midpoint of which represents an increase of 41% compared to FY15. $MYL forecasts revenue of about $10.5-11.5Bil, the midpoint of which represents a 16% increase compared to FY15.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?